chufangao/CTO huggingface dataset:
Clinical trial NCT04956302: Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma
Official title: A Phase I Study of Panobinostat in Combination With Daratumumab, Bortezomib, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Sponsor: Ohio State University Comprehensive Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: PI Decision
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-09-27
Primary completion date: 2022-06-16
Completion date: 2022-06-16
Plan to share individual participant data: NO
Clinical trial NCT05013437: Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT (Autologous Hematopoietic Cell Transplant) for Multiple Myeloma
Official title: A Pilot Study to Assess Impact of Low Dose Melphalan on Disease Burden Measured by Next Generation Sequencing Before Autologous Hematopoietic Cell Transplant (AHCT) for Multiple Myeloma Patients
Acronym: AHCT
Sponsor: Case Comprehensive Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: The original principal Investigator left the institution.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2023-09-30
Primary completion date: 2023-12-31
Completion date: 2024-03-31
Plan to share individual participant data: YES
IPD sharing description: All individual participant data (IPD) that underlie results in publication
Clinical trial NCT05393999: SABRE: A Single-arm Prospective Study Measuring Safety and Tolerability of SARS-CoV-2 Neutralising Antibodies in High-risk Populations
Official title: The SABRE Trial: A Single-arm Prospective Study Measuring Safety, Tolerability and Pharmacokinetics of Two SARS-CoV-2 Neutralising Antibodies (C135-LS and C144-LS) Amongst High-risk Special Populations of Vaccine Non-responders.
Acronym: SABRE
Sponsor: Imperial College Healthcare NHS Trust (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: The drug was found to be ineffective against Omicron, so the study was terminated and no patients were enrolled.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-11-29
Primary completion date: 2022-03-04
Completion date: 2022-03-04
Plan to share individual participant data: NO
Clinical trial NCT03981744: A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments
Official title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments
Sponsor: Janssen Pharmaceutical K.K. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: The study did not meet the primary endpoint.
Enrollment: 51.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-07-26
Primary completion date: 2022-01-24
Completion date: 2022-07-12
Limitations and caveats: This study was terminated early due to lack of efficacy found at Week 24.
Plan to share individual participant data: YES
IPD sharing description: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency.~As noted on this site, requests for access to the study data can be submitted through Yale open Data Access (YODA) Project site at yoda.yale.edu
Clinical trial NCT03675022: Effect of Dupilumab on Sleep Apnea in Patients With Rhinosinusitis
Official title: Effect of Dupilumab on Sleep Apnea Severity in Patients With Chronic Rhinosinusitis
Sponsor: Brigham and Women's Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: Inability to recruit during COVID
Enrollment: 9.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-08-15
Primary completion date: 2022-07-01
Completion date: 2022-07-01
Clinical trial NCT05679492: Study on the Safety and Efficacy of Meplazumab for Injection Patients COVID-19
Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled, add-on Phase III Clinical Study on the Efficacy and Safety of Meplazumab for Injection in Adults With Mild and Moderate COVID-19 Infections
Sponsor: Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Based on current epidemic situation in China, there is few Mild and Moderate COVID-19 patients.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-05-30
Primary completion date: 2023-09-01
Completion date: 2023-12-01
Clinical trial NCT04029922: Study of MT-5111 in HER2-positive Solid Tumors
Official title: A Phase 1 Open-label, Multicenter Dose Escalation and Expansion Study of MT-5111 in Subjects With Previously Treated Advanced HER2-positive Solid Tumors
Acronym: MT-5111
Sponsor: Molecular Templates, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Study Reprioritization
Enrollment: 50.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-11-12
Primary completion date: 2023-02-01
Completion date: 2023-04-27
Clinical trial NCT05536882: MC RCT - BPO vs Adapalene
Official title: Randomized Controlled Trial Comparing the Efficacy of Adapalene 0.1% Gel to 10% Benzoyl Peroxide in Treating Molluscum Contagiosum.
Sponsor: University of Oklahoma (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: The original PI left the institution prior to final IRB approval and the remaining study team did not have the resources to continue.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-05-18
Primary completion date: 2023-10-09
Completion date: 2023-10-09
Plan to share individual participant data: NO
Clinical trial NCT04757376: A Phase 3 Study to Compare Between CT-P41 and US-licensed Prolia in Postmenopausal Women With Osteoporosis
Official title: A Double-blind, Randomized, Active-controlled, Phase 3 Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety of CT-P41 and US-licensed Prolia in Postmenopausal Women With Osteoporosis
Sponsor: Celltrion (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 479.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-06-17
Primary completion date: 2023-05-18
Completion date: 2023-11-16
Baseline population: The overall number of participants analyzed represents the Intent-to-treat (ITT) Set. The ITT set was defined as all participants randomly assigned to receive study drug (CT-P41 or US-Prolia), regardless of whether or not any study drug was administered.
Clinical trial NCT03666988: First Time in Humans (FTIH) Study of GSK3368715 in Participants With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL)
Official title: A Phase I, Open-label, Dose-escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3368715 in Participants With Solid Tumors and DLBCL
Sponsor: GlaxoSmithKline (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Overall benefit-risk profile did not support continuation of the study
Enrollment: 31.0 (ACTUAL)
Number of arms: 5.0
Start date: 2018-10-22
Primary completion date: 2021-03-04
Completion date: 2021-03-04
Baseline population: Study was terminated early during Part 1 as the benefit/risk assessment did not favor continuation of the study, therefore Part 1: Food effect cohorts and Part 2 were not conducted.
Plan to share individual participant data: YES
IPD sharing description: IPD for this study will be made available via the Clinical Study Data Request site.
IPD time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.
IPD access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Clinical trial NCT03836287: Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-301)
Official title: A Multicenter, Randomized, Double-Blinded, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Topically Applied Sofpironium Bromide Gel, 15% in Subjects With Axillary Hyperhidrosis
Acronym: CardiganI
Sponsor: Botanix Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 350.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-10-09
Primary completion date: 2021-06-25
Completion date: 2021-06-25
Plan to share individual participant data: NO
Clinical trial NCT02601313: Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2)
Official title: A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects With Relapsed/Refractory Mantle Cell Lymphoma
Acronym: ZUMA-2
Sponsor: Gilead Sciences (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 105.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-11-09
Primary completion date: 2019-07-24
Completion date: 2023-09-22
Baseline population: The Safety Analysis Set included all participants treated with any dose of anti-CD19 CAR T cells.
Plan to share individual participant data: NO
Clinical trial NCT04364815: The University of the Philippines Hydroxychloroquine PEP Against COVID-19 Trial
Official title: Efficacy and Safety of Hydroxychloroquine for COVID-19 Post-Exposure Prophylaxis of Healthcare Workers in the Philippine General Hospital and UP Manila National Institutes of Health: A Randomized, Double-blind, Placebo-controlled Trial
Sponsor: University of the Philippines (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Investigators opted to change the design of the study.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-12-31
Primary completion date: 2021-05-31
Completion date: 2021-05-31
Plan to share individual participant data: NO
Clinical trial NCT02697253: Mechanisms Underlying Predictors of Success From Obesity Surgery
Official title: Mechanisms Underlying Predictors of Success From Obesity Surgery
Sponsor: Icahn School of Medicine at Mount Sinai (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Enrollment: 0.0 (ACTUAL)
Number of arms: 4.0
Start date: 2016-01-31
Primary completion date: 2021-07-29
Completion date: 2021-07-29
Plan to share individual participant data: NO
Clinical trial NCT04096560: A Study of TAK-994 in Adults With Type 1 and Type 2 Narcolepsy
Official title: A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Patients With Narcolepsy With or Without Cataplexy (Narcolepsy Type 1 or Narcolepsy Type 2)
Sponsor: Takeda (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: A safety signal has emerged in Phase 2 studies of TAK-994. As an immediate precautionary measure, Takeda has suspended dosing of patients and has decided to stop Phase 2 studies early.
Enrollment: 257.0 (ACTUAL)
Number of arms: 14.0
Start date: 2020-02-27
Primary completion date: 2021-11-05
Completion date: 2021-11-05
Plan to share individual participant data: YES
IPD sharing description: Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
IPD access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Clinical trial NCT04339413: A Study to Evaluate the Safety and Tolerability of Long-term Administration of Gantenerumab in Participants With Alzheimer's Disease (AD)
Official title: An Open-Label, Multicenter, Rollover Study to Evaluate the Safety and Tolerability of Long-Term Administration of Gantenerumab in Participants With Alzheimer's Disease
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Decision to terminate development of Gantenerumab for treatment of prodromal/mild/early stage Alzheimer's disease following results of a pre-planned analysis of the safety and efficacy of Gant in Graduate I\&II (WN29922/WN39658).
Enrollment: 116.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-05-22
Primary completion date: 2023-01-04
Completion date: 2023-01-04
Baseline population: Intent to treat (ITT) population included all the participants who were enrolled in the study.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Clinical trial NCT02605356: Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma
Official title: A Phase 1b/2 Trial to Evaluate the Safety and Efficacy of Radium-223 Dichloride (BAY88-8223) in Combination With Bortezomib and Dexamethasone in Early Relapsed Multiple Myeloma
Sponsor: Bayer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Study restarted under new study number 18987
Enrollment: 0.0 (ACTUAL)
Number of arms: 5.0
Start date: 2016-10-31
Primary completion date: 2019-11-30
Completion date: 2021-07-31
Clinical trial NCT03886493: Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer
Official title: Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Low accrual due to COVID-19 pandemic.
Enrollment: 7.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-08-28
Primary completion date: 2020-10-06
Completion date: 2020-10-06
Plan to share individual participant data: NO
Clinical trial NCT02657434: A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)
Official title: A Phase III, Open-Label, Randomized Study of Atezolizumab (MPDL3280A, Anti-Pd-L1 Antibody) in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Patients Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 578.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-04-30
Primary completion date: 2019-07-18
Completion date: 2022-12-13
Clinical trial NCT04802031: Rapid-infusion Isatuximab in Relapsed/Refractory Multiple Myeloma
Official title: Safety of Rapid-Infusion Isatuximab in Patients With Relapsed/Refractory Multiple Myeloma
Sponsor: University of California, San Francisco (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Low accrual
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-05-28
Primary completion date: 2022-11-30
Completion date: 2022-12-31
Plan to share individual participant data: NO
Clinical trial NCT04181723: Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)
Official title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome
Sponsor: ACADIA Pharmaceuticals Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 187.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-11-06
Primary completion date: 2021-10-28
Completion date: 2021-10-28
Clinical trial NCT05110781: Atezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck Squamous Cell Cancer With an Unknown or Historic Primary Site
Official title: Neo-Adjuvant Atezolizumab Prior to Definitive Surgical Resection of Regionally Metastatic Head &Amp; Neck Cutaneous Squamous Cell Carcinoma With an Unknown or Historic Primary Site: A Window Trial
Sponsor: University of California, Davis (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Slow accrual
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-12-07
Primary completion date: 2022-05-02
Completion date: 2023-04-18
Limitations and caveats: One participant was enrolled in study prior to termination. Enrollment in the clinical trial did not reach the target number of participants needed to achieve target power and was insufficient to produce statistically reliable results.
Clinical trial NCT04682249: Systemic Chemotherapy, Apatinib Plus Sintilimab for Metastasis ICC
Official title: Systemic Chemotherapy Based on Oxaliplatin and 5-fluorouracil, Apatinib Plus Sintilimab for Metastasis ICC: a Single Arm Prospective Study
Sponsor: Sun Yat-sen University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: no patients enrolled
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-12-01
Primary completion date: 2021-02-01
Completion date: 2021-02-01
Clinical trial NCT03136653: A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma
Official title: A Phase 2 Open-label, Single-arm, Multicenter Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Refractory and Relapsed Multiple Myeloma
Sponsor: Molecular Partners AG (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 33.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-05-23
Primary completion date: 2020-10-12
Completion date: 2021-01-13
Plan to share individual participant data: NO
Clinical trial NCT02897050: Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer
Official title: Phase II Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: SUSPENDED 
Enrollment: 170.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2016-09-30
Primary completion date: 2022-12-31
Completion date: 2024-09-30
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03656744: A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)
Official title: A Proof-of-Concept and Dose-Ranging Study Investigating the Efficacy and Safety of HTD1801 in Adults With NASH and T2DM
Sponsor: HighTide Biopharma Pty Ltd (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 101.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-11-26
Primary completion date: 2020-02-07
Completion date: 2020-03-09
Baseline population: One-hundred one subjects were randomized into the study, however, subject did not receive investigational study drug and was not included in the efficacy or safety analyses data sets.
Limitations and caveats: The study was conducted exclusively in the United States and data may not be applicable to other populations. The study enrolled subjects with presumed NASH and diabetes. Further studies to determine the effect of HTD1801 in non-diabetics may be needed. Future studies will focus on patients with biopsy confirmed NASH and use liver histology (i.e., liver biopsies) as a histological endpoint.
Plan to share individual participant data: NO
Clinical trial NCT04855240: Evaluate the Efficacy and Safety of ACP-044 for the Treatment of Acute Postoperative Pain Following Bunionectomy
Official title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ACP-044 for Acute Postoperative Pain Following Orthopedic Surgery (Bunionectomy)
Sponsor: ACADIA Pharmaceuticals Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 239.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-03-29
Primary completion date: 2022-02-11
Completion date: 2022-03-14
Plan to share individual participant data: NO
Clinical trial NCT04878315: Bioequivalence Study Between Capoten Versus Captopril Reference Product in Healthy Adult Participants Under Fasting Conditions
Official title: An Open-label, Randomized Three Period, Three Sequence, Partially Replicated Crossover Bioequivalence Study of Two Oral Formulations of Captopril 50 mg Film Coated Tablets in Healthy Adult Participants Under Fasting Conditions
Sponsor: GlaxoSmithKline (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Internal sponsor decision to terminate project prematurely based on a waiver granted by Egypt EDA (Egyptian drug authority). No subjects were enrolled.
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-02-13
Primary completion date: 2022-03-25
Completion date: 2022-03-25
Plan to share individual participant data: YES
IPD sharing description: IPD for this study will be made available via the Clinical Study Data Request site.
IPD time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, a key secondary endpoints and safety data of the study.
IPD access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Clinical trial NCT02985177: A RCT of a Combination of Analgesics for Pain Management in Children With a Suspected Fracture
Official title: A Randomized Controlled Trial of a Combination of Analgesics for Pain Management in Children With a Suspected Fracture at Triage (CAST Trial)
Acronym: CAST
Sponsor: St. Justine's Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: We couldn't obtain funds for this study
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-01-31
Primary completion date: 2021-07-31
Completion date: 2021-09-30
Plan to share individual participant data: NO
Clinical trial NCT05281562: Immunonutrition for Diabetic Foot Ulcers
Official title: Effects of Supplemental Immunonutrition on Healing of Chronic Non-Healing Lower Extremity Ulcers in Diabetic Patients: A Pilot Study
Sponsor: Prisma Health-Midlands (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: There are not enough patients at our institution meeting eligibility criteria to complete the study as intended.
Enrollment: 1.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-07-01
Primary completion date: 2023-03-20
Completion date: 2023-03-20
Plan to share individual participant data: NO